GR1007906B - Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου - Google Patents

Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου

Info

Publication number
GR1007906B
GR1007906B GR20120100173A GR20120100173A GR1007906B GR 1007906 B GR1007906 B GR 1007906B GR 20120100173 A GR20120100173 A GR 20120100173A GR 20120100173 A GR20120100173 A GR 20120100173A GR 1007906 B GR1007906 B GR 1007906B
Authority
GR
Greece
Prior art keywords
preparation
pharmaceutical composition
composition containing
carbonic anhydrase
anhydrase inhibitor
Prior art date
Application number
GR20120100173A
Other languages
English (en)
Inventor
Ευαγγελος Ανδρεα Καραβας
Ευθυμιος Χρηστου Κουτρης
Ιωαννα Χρηστου Κουτρη
Βασιλικη Χρηστου Σαμαρα
Ευσταθια Μυλουλη
Original Assignee
Φαρματεν Αβεε,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Φαρματεν Αβεε, filed Critical Φαρματεν Αβεε,
Priority to GR20120100173A priority Critical patent/GR1007906B/el
Priority to ZA2013/01665A priority patent/ZA201301665B/en
Priority to HRP20191151TT priority patent/HRP20191151T1/hr
Priority to US14/386,604 priority patent/US20150080385A1/en
Priority to SI201331483T priority patent/SI2827838T1/sl
Priority to SM20190349T priority patent/SMT201900349T1/it
Priority to TR2019/09163T priority patent/TR201909163T4/tr
Priority to DK13710972.4T priority patent/DK2827838T3/da
Priority to RS20190660A priority patent/RS58814B1/sr
Priority to ES13710972T priority patent/ES2731754T3/es
Priority to PL13710972T priority patent/PL2827838T3/pl
Priority to LTEP13710972.4T priority patent/LT2827838T/lt
Priority to PCT/EP2013/000697 priority patent/WO2013139444A1/en
Priority to CA2866810A priority patent/CA2866810C/en
Priority to AU2013234721A priority patent/AU2013234721A1/en
Priority to PT13710972T priority patent/PT2827838T/pt
Priority to HUE13710972A priority patent/HUE043906T2/hu
Priority to EP13710972.4A priority patent/EP2827838B1/en
Publication of GR1007906B publication Critical patent/GR1007906B/el
Priority to CY20191100488T priority patent/CY1122598T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σταθερή φαρμακευτική σύνθεση για τοπική χρήση που περιέχει μια θεραπευτικά δραστική ποσότητα Βρινζολαμίδης ή οφθαλμολογικά αποδεκτών αλάτων αυτής και επαρκή ποσότητα ενός επιφανειοδραστικού, όπως πολοξαμερές, για χρήση στην αντιμετώπιση της οφθαλμικής υπέρτασης και του γλαυκώματος.
GR20120100173A 2012-03-22 2012-03-22 Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου GR1007906B (el)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GR20120100173A GR1007906B (el) 2012-03-22 2012-03-22 Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
ZA2013/01665A ZA201301665B (en) 2012-03-22 2013-03-05 Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
ES13710972T ES2731754T3 (es) 2012-03-22 2013-03-08 Composición farmacéutica oftalmica que contiene un inhibidor de anhidrasa carbónica y método para la preparación de la misma
LTEP13710972.4T LT2827838T (lt) 2012-03-22 2013-03-08 Farmacinė kompozicija akims, kurios sudėtyje yra karboanhidrazės inhibitorius, ir jos paruošimo būdas
SI201331483T SI2827838T1 (sl) 2012-03-22 2013-03-08 Oftalmični farmacevtski sestavek, ki vsebuje inhibitor ogljikove anhidraze, in postopek za pripravo le-tega
SM20190349T SMT201900349T1 (it) 2012-03-22 2013-03-08 Composizione farmaceutica oftalmica contenente un inibitore dell'anidrasi carbonica e metodo per la preparazione della stessa
TR2019/09163T TR201909163T4 (tr) 2012-03-22 2013-03-08 Bir karbonik anhidraz inhibitörü içeren oftalmik farmasötik bileşim ve bunun hazırlanması için yöntem.
DK13710972.4T DK2827838T3 (da) 2012-03-22 2013-03-08 Oftalmisk farmaceutisk sammensætning, der indeholder en carboanhydrasehæmmer og fremgangsmåde til fremstilling heraf
RS20190660A RS58814B1 (sr) 2012-03-22 2013-03-08 Oftalmološka farmaceutska kompozicija koja sadrži inhibitor karbonske anhidraze i postupak za njeno dobijanje
HRP20191151TT HRP20191151T1 (hr) 2012-03-22 2013-03-08 Oftalmološki farmaceutski sastav koji sadrži inhibitor ugljične anhidraze i metoda za pripremu istog
PL13710972T PL2827838T3 (pl) 2012-03-22 2013-03-08 Kompozycja farmaceutyczna do oczu zawierająca inhibitor anhydrazy węglanowej i sposób jej wytwarzania
US14/386,604 US20150080385A1 (en) 2012-03-22 2013-03-08 Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
PCT/EP2013/000697 WO2013139444A1 (en) 2012-03-22 2013-03-08 Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
CA2866810A CA2866810C (en) 2012-03-22 2013-03-08 Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
AU2013234721A AU2013234721A1 (en) 2012-03-22 2013-03-08 Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
PT13710972T PT2827838T (pt) 2012-03-22 2013-03-08 Composição farmacêutica oftálmica contendo um inibidor da anidrase carbónica e método para a sua preparação
HUE13710972A HUE043906T2 (hu) 2012-03-22 2013-03-08 Karbo-anhidráz gátlót tartalmazó szemészeti gyógyszerkészítmény, és eljárás annak elõállítására
EP13710972.4A EP2827838B1 (en) 2012-03-22 2013-03-08 Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof
CY20191100488T CY1122598T1 (el) 2012-03-22 2019-05-07 Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20120100173A GR1007906B (el) 2012-03-22 2012-03-22 Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου

Publications (1)

Publication Number Publication Date
GR1007906B true GR1007906B (el) 2013-05-30

Family

ID=47913366

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20120100173A GR1007906B (el) 2012-03-22 2012-03-22 Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου

Country Status (19)

Country Link
US (1) US20150080385A1 (el)
EP (1) EP2827838B1 (el)
AU (1) AU2013234721A1 (el)
CA (1) CA2866810C (el)
CY (1) CY1122598T1 (el)
DK (1) DK2827838T3 (el)
ES (1) ES2731754T3 (el)
GR (1) GR1007906B (el)
HR (1) HRP20191151T1 (el)
HU (1) HUE043906T2 (el)
LT (1) LT2827838T (el)
PL (1) PL2827838T3 (el)
PT (1) PT2827838T (el)
RS (1) RS58814B1 (el)
SI (1) SI2827838T1 (el)
SM (1) SMT201900349T1 (el)
TR (1) TR201909163T4 (el)
WO (1) WO2013139444A1 (el)
ZA (1) ZA201301665B (el)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009616B (el) * 2018-07-20 2019-10-11 Φαρματεν Α.Β.Ε.Ε. Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6704400B2 (ja) * 2014-10-20 2020-06-03 センティス・ファーマ・プライヴェート・リミテッド 眼科用液剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
CA2607608A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
CN102341114A (zh) * 2009-03-03 2012-02-01 加拿大瑞发生物科技制药集团 用于预防和治疗流感的植物提取物组合物
EP2394637A1 (en) 2010-05-21 2011-12-14 Zaklady Farmaceutyczne Polpharma SA Process for obtaining sterile brinzolamide suspensions
WO2013025696A1 (en) * 2011-08-15 2013-02-21 Teva Pharmaceutical Industries Ltd. Ophthalmic formulations and processes for their preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1009616B (el) * 2018-07-20 2019-10-11 Φαρματεν Α.Β.Ε.Ε. Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει βρινζολαμιδη και τιμολολη και μεθοδος παρασκευης αυτου

Also Published As

Publication number Publication date
SI2827838T1 (sl) 2019-07-31
ES2731754T3 (es) 2019-11-18
ZA201301665B (en) 2013-12-23
CA2866810C (en) 2021-04-06
EP2827838A1 (en) 2015-01-28
AU2013234721A1 (en) 2014-10-30
PT2827838T (pt) 2019-06-05
PL2827838T3 (pl) 2019-09-30
HUE043906T2 (hu) 2019-09-30
SMT201900349T1 (it) 2019-09-09
TR201909163T4 (tr) 2019-07-22
RS58814B1 (sr) 2019-07-31
CY1122598T1 (el) 2021-01-27
WO2013139444A1 (en) 2013-09-26
LT2827838T (lt) 2019-05-10
EP2827838B1 (en) 2019-03-27
US20150080385A1 (en) 2015-03-19
CA2866810A1 (en) 2013-09-26
HRP20191151T1 (hr) 2019-10-04
DK2827838T3 (da) 2019-07-01

Similar Documents

Publication Publication Date Title
IN2014MN01755A (el)
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
JO3551B1 (ar) تركيبة كبسولة مشتملة على المونتليوكاست و اللِّيفوسيتريزين
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201490515A1 (ru) Новые ингибиторы rock-киназ
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
NZ708526A (en) Novel rock inhibitors
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
TN2013000533A1 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
EA201490573A1 (ru) Соединение бензотиазолона
EA201500669A1 (ru) Офтальмологическая фармацевтическая композиция для наружного применения, содержащая регорафениб
GR1007906B (el) Οφθαλμικο φαρμακευτικο σκευασμα περιεχον ενα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτου
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
WO2012134187A3 (ko) 황반변성 예방 또는 치료용 약학 조성물
GR1007881B (el) Οφθαλμικο φαρμακευτικο σκευασμα περιεχον δορζολαμιδη και τιμολολη και μεθοδος για την παρασκευη αυτου
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
WO2013151719A3 (en) Fluorinated oxazolidinone derivatives
GR1008509B (el) Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δορζολαμιδη
GR1008510B (el) Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον ενα αναλογο προσταγλαδινης
GR1008505B (el) Οφθαλμικο φαρμακευτικο σκευασμα ελευθερο συντηρητικου περιεχον δορζολαμιδη και τιμολολη
GR1008527B (el) Οφθαλμικο φαρμακευτικο σκευασμα ελευθερο συντηρητικου περιεχον βιματοπροστη

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20130614